Insilico Medicine uses AI to transform and revolutionize the drug development process. Recently, they achieved a great milestone with the development of the first GenAI drug, which has entered Phase II clinical trials.
We extend our congratulations to the Head of the LongeVC Scientific Advisory Board, Alex Zhavoronkov, and the Insilico Medicine team. Insilico Medicine is one of our portfolio companies, and we eagerly anticipate its continued growth and impact in the industry, particularly after securing a $500M deal with Menarini Group.
Learn more about this exciting development in the recent Forbes article here.
We extend our congratulations to the Head of the LongeVC Scientific Advisory Board, Alex Zhavoronkov, and the Insilico Medicine team. Insilico Medicine is one of our portfolio companies, and we eagerly anticipate its continued growth and impact in the industry, particularly after securing a $500M deal with Menarini Group.
Learn more about this exciting development in the recent Forbes article here.